Artivion announces data from AMDS PERSEVERE and PROTECT trials

Artivion (AORT) announced data from its AMDS PERSEVERE and PROTECT trials were presented in Late-Breaking Science presentations at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, Denmark. The AMDS PERSEVERE trial presentation highlighted positive 30-day data focused on a subset of patients with visceral and renal malperfusion. The results demonstrate resolution of visceral malperfusion in 83% and renal malperfusion in 74% of affected subjects following AMDS implantation. Real-world results from the AMDS PROTECT trial further confirm the statistically significant positive clinical outcomes demonstrated in the PERSEVERE IDE study.